The Global Health Body Issues Concern Over Critical Lack of Obesity Medications
Less than one in 10 people that would benefit from obesity jabs including Wegovy have access to them, states the WHO as it releases its first advice on the medications.
With more than one billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer availability to these injectable treatments.
Per projections, more than two billion will be obese by 2030 if no action is taken.
"Our latest guidelines acknowledges that obesity is a long-term condition that can be managed with holistic and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are key barriers to widespread availability to the treatments that can aid individuals in losing substantial weight, says the body.
GLP-1 Therapy Supply Crisis
Even in the current most favorable case, the supply of such drugs would only suffice for approximately 100 million people – under 10% of those who need them, per the health organization.
The guideline urges nations and manufacturers to increase availability, via approaches like licensing agreements.
Exclusive production rights on the active ingredient – the main component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Jabs Function
The injections imitate a natural hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so individuals reduce food intake.
People usually start to lose weight within a few weeks of beginning the regular doses.
Studies points to patients may see weight return after a year of halting the treatment, as their normal hunger return.
Being overweight or obese increases your chance for experiencing health problems, like diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity impacts people in countries worldwide and was linked to millions of deaths worldwide in 2024, per the health agency.